An injection of rAAV carrying either XIAP or GFP was delivered to the subretinal space of the left eye of each rat. The right eye served as an untreated control. Animals were anesthetized by 2% isoflurane gas inhalation. Eyes were dilated using 1% tropicamide (Mydriacyl; Alcon Canada, Mississauga, ON, Canada) and 2.5% phenylephrine hydrochloride (Mydfrin; Alcon). Proparacaine hydrochloride drops (0.5%, Alcaine; Alcon) were administered as a local anesthetic. Pain management was achieved by buprenorphine injection (0.04 mg/kg). To maintain lubrication throughout the procedure, 0.3% hypromellose (Genteal gel; Novartis Pharmaceuticals, Mississauga, ON, Canada) was applied to the eye. Subretinal injections were performed by creating a sclerotomy approximately 2 mm posterior to the limbus with a 20-gauge V-lance knife (Alcon). Care was taken to avoid lens contact because this could induce cataract development. A coverslip coated with 0.3% hypromellose (Genteal gel; Novartis Pharmaceuticals) was placed on top of the eye to provide magnification and visualization of the back of the eye. A 33-gauge blunt needle attached to a 10-μL syringe (Hamilton, Reno, NV) was inserted through the scleral puncture, guided lateral to the lens, and inserted through the retina. rAAV-XIAP or rAAV-GFP (2-μL vol) combined with fluorescein tracer (50:1 vol/vol) was delivered to the subretinal space of the eye. The fluorescein allowed for immediate visualization and evaluation of the injection location, enabling ascertainment of a successful subretinal delivery. Injections were delivered in a consistent manner between the 12:00 and 2:00 positions. Postsurgical care consisted of administration of the antibiotic 0.3% ciprofloxacin hydrochloride (Ciloxan; Alcon) and a nonsteroidal anti-inflammatory drug, 0.03% flurbiprofen sodium (Ocufen; Allergan, Irvine, CA), for 5 days after injection.